FDA approves cemiplimab-rwlc in combination with platinum-based chemotherapy for non-small cell lung cancer

[FDA]

On November 8, 2022, the Food and Drug Administration approved cemiplimab-rwlc (Libtayo, Regeneron Pharmaceuticals, Inc.) in combination with platinum-based chemotherapy for adult patients with advanced non-small cell lung cancer (NSCLC) with no EGFR, ALK, or ROS1 aberrations.


Baca selengkapnya di : http://www.fda.gov...